Adamas named 2021 finalist in the new therapeutics category of the ucsf health awards

Emeryville, calif.--(business wire)--adamas pharmaceuticals, inc. (nasdaq: adms), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been selected as one of five finalists in the ucsf health awards 2021 new therapeutics category. this year's ucsf health awards program, which historically focused on the digital health tech industry, was expanded to include several life science categories
ADMS Ratings Summary
ADMS Quant Ranking